Stock Track | Recursion Pharmaceuticals Plunges 5.35% as BofA Cuts Price Target

Stock Track01-08

Recursion Pharmaceuticals, Inc. (RXRX) stock plummeted 5.35% in Tuesday's intraday trading session, underperforming the broader market. This significant drop followed a price target cut by Bank of America Securities analysts.

According to the provided news, BofA Securities analysts lowered their price target on RXRX from $12 to $10, maintaining a Neutral rating. While the specific reasons for the price target reduction were not mentioned, analysts often adjust targets based on changes in their financial projections, valuation models, or industry outlooks.

Despite the price target cut by BofA, other analysts polled by FactSet still have an average rating of Overweight on RXRX, with a mean price target of $9.50. This suggests a potential upside from the current levels, although the recent downward revision may have dampened investor sentiment in the short term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148847680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148847680","market":"hk","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Plunges 5.35% as BofA Cuts Price Target","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) stock plummeted 5.35% in Tuesday's intraday trading session, underperforming the broader market. This significant drop followed a price target cut by Bank of America Securities analysts.</p>\n\n<p>According to the provided news, BofA Securities analysts lowered their price target on RXRX from $12 to $10, maintaining a Neutral rating. While the specific reasons for the price target reduction were not mentioned, analysts often adjust targets based on changes in their financial projections, valuation models, or industry outlooks.</p>\n\n<p>Despite the price target cut by BofA, other analysts polled by FactSet still have an average rating of Overweight on RXRX, with a mean price target of $9.50. This suggests a potential upside from the current levels, although the recent downward revision may have dampened investor sentiment in the short term.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Plunges 5.35% as BofA Cuts Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Plunges 5.35% as BofA Cuts Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-08 00:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) stock plummeted 5.35% in Tuesday's intraday trading session, underperforming the broader market. This significant drop followed a price target cut by Bank of ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1148847680","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148847680","pubTimestamp":1736266585,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc.  stock plummeted 5.35% in Tuesday's intraday trading session, underperforming the broader market. This significant drop followed a price target cut by Bank of America Securities analysts.According to the provided news, BofA Securities analysts lowered their price target on RXRX from $12 to $10, maintaining a Neutral rating. While the specific reasons for the price target reduction were not mentioned, analysts often adjust targets based on changes in their financia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"美国银行下调目标价，Recursion Pharmaceuticals股价暴跌5.35%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) stock plummeted 5.35% in Tuesday's intraday trading session, underperforming the broader market. This significant drop followed a price target cut by Bank of America Securities analysts.\nAccording to the provided news, BofA Securities analysts lowered their price target on RXRX from $12 to $10, maintaining a Neutral rating. While the specific reasons for the price target reduction were not mentioned, analysts often adjust targets based on changes in their financial projections, valuation models, or industry outlooks.\nDespite the price target cut by BofA, other analysts polled by FactSet still have an average rating of Overweight on RXRX, with a mean price target of $9.50. This suggests a potential upside from the current levels, although the recent downward revision may have dampened investor sentiment in the short term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148847680"}